Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Conspirituality

67: The Promise & Peril of Psychedelics

03 Sep 2021

Description

Psychedelics are all the rage in the investment world, with hundreds of millions of dollars pouring into research-based startups in the hope of finding interventions for addiction, depression, PTSD, end-of-life anxieties, and much more. But is it too much? Are we, as has happened with numerous substances in the past, placing too much faith in plant medicine? Will investors expecting a return on investment skew the research? And, more to the point of this podcast, is the burgeoning crop of yoga instructors turned shamans promising more than they can deliver?With Matthew on a much-deserved vacation this week, Julian interviews Derek about these topics based on Derek’s 2020 book, Hero’s Dose: The Case for Psychedelics in Ritual & Therapy.In the Ticker this week, Julian looks at the growing list of anti-vax, COVID-is-a-hoax conservative radio hosts dying of COVID. We begin with the obvious: Joe Rogan recently contracted COVID, and admitted to undergoing what might be the most insane drug regimen to date.Show NotesRobert David Steele Dies from Covid, While Denying CovidAnti-Vax Conservative Radio Hosts Dying from CovidCaleb Wallace, 30-year-old Freedom Rally Organizer Dies from CovidTexas GOP official who Mocked Covid, dies from itHero’s Dose: The Case for Psychedelics in Ritual & Therapy -- -- --Support us on PatreonPre-order Conspirituality: How New Age Conspiracy Theories Became a Health Threat: America | Canada Follow us on Instagram | Twitter: Derek | Matthew | JulianOriginal music by EarthRise SoundSystem Learn more about your ad choices. Visit megaphone.fm/adchoices

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.